Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-11-18Clinical Trial Update: A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients [Phase 4]
Phase 4, open-label, non-randomized clinical trial evaluating whether natalizumab improves ambulatory measures in relapsing-remitting multip…
-
CLINICAL_TRIALS trial_result · 2014-10-21Clinical Trial Update: Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 2, Phase 3]
Phase 2/3 clinical trial of natalizumab (BG00002, Tysabri) in Japanese participants with relapsing-remitting multiple sclerosis has complete…
-
CLINICAL_TRIALS withdrawal · 2014-09-30Clinical Trial Update: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS [Phase 4]
Novartis' Phase 4 trial evaluating an individualized patient support program for treatment satisfaction in fingolimod-treated Relapsing-remi…
-
CLINICAL_TRIALS trial_result · 2014-09-25Clinical Trial Update: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression [Phase 4]
A Phase 4 trial evaluated adding antidepressants to fingolimod in patients with relapsing-remitting multiple sclerosis and depression; the s…
-
CLINICAL_TRIALS withdrawal · 2014-09-15Clinical Trial Update: Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial evaluating PEGylated interferon beta-1a (BIIB017) for Relapsing-Remitting Multiple Sclerosis was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-09-09Clinical Trial Update: Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) [Phase 1]
Phase 1 safety study of Natalizumab in multiple sclerosis has completed. The update highlights safety and tolerability data from this early-…
-
CLINICAL_TRIALS trial_result · 2014-08-13Clinical Trial Update: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis [Phase 3]
A Phase 3 trial evaluating Rebif, Copaxone, and Tysabri for active Relapsing Remitting Multiple Sclerosis was terminated with results posted…
-
CLINICAL_TRIALS trial_result · 2014-08-08Clinical Trial Update: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) [Phase 4]
This Phase 4 trial update assesses patient-reported outcomes in relapsing-remitting multiple sclerosis patients who switched to fingolimod 0…
-
CLINICAL_TRIALS trial_result · 2014-07-31Clinical Trial Update: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
An update on a real-world study evaluating Rebif with a new formulation, focusing on safety, tolerability, and patient adherence in relapsin…
-
CLINICAL_TRIALS research · 2014-07-16Clinical Trial Update: A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
This is a completed Scandinavian non-interventional study assessing adherence to Rebif administered with the RebiSmart auto-injector in rela…
-
CLINICAL_TRIALS trial_result · 2014-07-16Clinical Trial Update: An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
This completed observational study evaluated adherence and persistence to Rebif therapy in relapsing-remitting multiple sclerosis and explor…
-
CLINICAL_TRIALS research · 2014-07-14Clinical Trial Update: An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
This completed observational study evaluated whether high-frequency and higher-dose administration of Rebif (interferon beta-1a) could optim…
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
A completed proof-of-concept trial evaluating the effect of natalizumab (Tysabri) on bladder function in relapsing-remitting multiple sclero…
-
CLINICAL_TRIALS trial_result · 2014-06-04Clinical Trial Update: fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
This completed trial used fMRI to compare brain activity related to treatment recommendations in recently diagnosed relapsing-remitting mult…
-
CLINICAL_TRIALS trial_result · 2014-06-02Clinical Trial Update: Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis [Phase 3]
This clinical trial update reports efficacy and safety results from a Phase 3 study of oral BG00012 (dimethyl fumarate) versus an active ref…
-
CLINICAL_TRIALS trial_result · 2014-06-02Clinical Trial Update: Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis [Phase 3]
This update reports the Phase 3 results for the oral agent BG00012 in relapsing-remitting multiple sclerosis, focusing on efficacy and safet…
-
CLINICAL_TRIALS trial_result · 2014-05-20Clinical Trial Update: Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 4]
Phase 4 clinical trial update showing safety and efficacy data for Natalizumab (Tysabri) in Russian participants with relapsing-remitting mu…
-
CLINICAL_TRIALS trial_result · 2014-05-08Clinical Trial Update: Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis
Clinical trial update describing the effect of fingolimod on cardiac autonomic regulation in patients with relapsing-remitting multiple scle…
-
CLINICAL_TRIALS trial_result · 2014-04-17Clinical Trial Update: Natalizumab De-escalation With Interferon Beta-1b [Phase 4]
Phase 4 trial evaluating de-escalation of natalizumab with interferon beta-1b in relapse-remitting multiple sclerosis; the study completed a…
-
CLINICAL_TRIALS trial_result · 2014-04-11Clinical Trial Update: Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis [Phase 2]
This is a Phase 2 trial update of intravenous immune globulin (IGIV) for relapsing-remitting multiple sclerosis, with results posted in 2014…
-
CLINICAL_TRIALS trial_result · 2014-04-04Clinical Trial Update: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod [Phase 3]
A Phase 3 trial assessing disease control and safety in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingol…
-
CLINICAL_TRIALS research · 2014-04-04Clinical Trial Update: Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis [NA]
Clinical trial update on a 12-week respiratory muscle training program for Relapsing-remitting multiple sclerosis; the current status of the…
-
CLINICAL_TRIALS trial_result · 2014-04-03Clinical Trial Update: Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx [Phase 3]
Phase 3 MSCombiRx trial evaluating combination therapy with interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclero…
-
CLINICAL_TRIALS trial_result · 2014-04-02Clinical Trial Update: An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 trial evaluating a new daily subcutaneous formulation of glatiramer acetate for relapsing-remitting multiple sclerosis was terminate…
-
CLINICAL_TRIALS trial_result · 2014-03-18Clinical Trial Update: An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
Observational study assessing outcomes for relapsing-remitting MS patients who start or restart baseline interferon beta-1a after prior esca…